Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 202611 Citations
Pasireotide (Signifor)8 residuesFCFWKTCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Pasireotide (Signifor) is the first FDA-approved medical therapy that directly targets pituitary tumors in Cushing's disease. It binds all five somatostatin receptor subtypes with the strongest affinity for SSTR5. Normalizes urinary free cortisol in roughly 26% of patients, but hyperglycemia in 73% requires concurrent antidiabetic management.
600mcg · 2x Daily
Summary: Add 0mL BAC water to your 0.3mg vial. Draw to < 0.1 units on a U-100 syringe for a 600mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 600mcg | 2x Daily |
| Moderate | 600mcg | 2x Daily |
| Aggressive | 900mcg | 2x Daily |
Pasireotide is not a research peptide you'll reconstitute from a lyophilized vial. Signifor SC comes as pre-filled, single-use ampules in three concentrations: 0.3 mg/mL, 0.6 mg/mL, and 0.9 mg/mL. Each ampule holds 1 mL. You draw the full contents and inject subcutaneously into the abdomen or thigh. The 600 mcg dose uses one 0.6 mg/mL ampule per injection, twice daily. The 900 mcg dose uses one 0.9 mg/mL ampule. No measuring, no bacteriostatic water, no math. Verify the ampule concentration matches your prescribed dose before each shot. Spacing matters. Doses need to be roughly 12 hours apart. Intervals stretching beyond 14 hours reduce steady-state plasma exposure and may compromise efficacy. The most common beginner mistake: ignoring blood glucose. Buy a glucometer before you start. Test fasting glucose daily for the first two weeks. If readings cross 126 mg/dL, contact your endocrinologist about starting metformin. This is not something to wait on. Store ampules at 2 to 8 degrees C. Do not freeze. Protect from light. Each ampule is single-use; discard any leftover.
Dosing based on Signifor (pasireotide) FDA Prescribing Information (2020) — 17 published references.View all sources →
Cross-check your Pasireotide (Signifor) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Pasireotide (Signifor) is the first FDA-approved medical therapy that directly targets pituitary tumors in Cushing's disease. It binds all five somatostatin receptor subtypes with the strongest affinity for SSTR5. Normalizes urinary free cortisol in roughly 26% of patients, but hyperglycemia in 73% requires concurrent antidiabetic management.
